These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 17990791

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
    [Abstract] [Full Text] [Related]

  • 3. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.
    J Mol Biol; 2007 May 04; 368(3):652-65. PubMed ID: 17362988
    [Abstract] [Full Text] [Related]

  • 4. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    Meissner HC, Long SS, American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec 04; 112(6 Pt 1):1447-52. PubMed ID: 14654628
    [Abstract] [Full Text] [Related]

  • 5. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection.
    Robinson RF, Nahata MC.
    Am J Health Syst Pharm; 2000 Feb 01; 57(3):259-64. PubMed ID: 10674778
    [Abstract] [Full Text] [Related]

  • 6. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec 01; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [Abstract] [Full Text] [Related]

  • 7. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
    Weisman LE.
    Curr Opin Mol Ther; 2009 Apr 01; 11(2):208-18. PubMed ID: 19330726
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.
    Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA.
    J Infect Dis; 2011 Mar 01; 203(5):674-82. PubMed ID: 21208913
    [Abstract] [Full Text] [Related]

  • 10. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
    Resch B, Müller W.
    Klin Padiatr; 1999 Mar 01; 211(6):450-5. PubMed ID: 10592925
    [Abstract] [Full Text] [Related]

  • 11. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
    Groothuis JR, Nishida H.
    Pediatr Int; 2002 Jun 01; 44(3):235-41. PubMed ID: 11982888
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
    Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, Wrapp D, Patel NK, Cook KE, Richter BWM, Ryan PC, Yuan AQ, Suzich JA.
    Sci Transl Med; 2017 May 03; 9(388):. PubMed ID: 28469033
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
    Piedimonte G, King KA, Holmgren NL, Bertrand PJ, Rodriguez MM, Hirsch RL.
    Pediatr Res; 2000 Mar 03; 47(3):351-6. PubMed ID: 10709734
    [Abstract] [Full Text] [Related]

  • 16. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, Glenn G, Ellingsworth L, Smith G.
    Vaccine; 2018 Dec 18; 36(52):8069-8078. PubMed ID: 30389195
    [Abstract] [Full Text] [Related]

  • 17. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
    Huang K, Wu H.
    Microbiol Spectr; 2014 Aug 18; 2(4):AID-0014-2014. PubMed ID: 26104207
    [Abstract] [Full Text] [Related]

  • 18. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.
    Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF.
    J Mol Biol; 2005 Jul 01; 350(1):126-44. PubMed ID: 15907931
    [Abstract] [Full Text] [Related]

  • 19. Strategies for preventing respiratory syncytial virus.
    Forbes M.
    Am J Health Syst Pharm; 2008 Dec 01; 65(23 Suppl 8):S13-9. PubMed ID: 19020197
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.